BUSINESS

Parexel Helping Japan Address Drug Loss with “Ethnobridging” Studies, PI Still a Hurdle

By Takashi Ebisawa March 29, 2024

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Japanese PI studies still pose a barrier for global companies to develop their medicines in Japan despite the recent regulatory reforms by local authorities, says a senior official of Parexel International. The US CRO hopes to see drug makers tap…

To read the full story

Japan Officially Drops Japanese PI Requirement before Global Trial Entry
December 26, 2023

BUSINESS

Hisamitsu Starts Promotion of Yaz AGs under Bayer Alliance
March 11, 2026
Seagen ADC Patent Dispute Ends with Daiichi Sankyo Victory
March 11, 2026
Seikagaku Re-Files Herniated Disk Drug with US FDA
March 11, 2026
Lotte to Step Up CVC Investments to Drive CDMO Synergies
March 10, 2026
Ipsen to Withdraw Tazverik Overseas over Secondary Cancer Risk
March 10, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

ICH Weighs Need for Biosimilar Efficacy Trials as Regulators Move Away from Routine Use

By Takashi Ebisawa

International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…